Breaking News

OncoMed, Lilly Enter Clinical Supply Pact

Will evaluate Alimta and carboplatin with Demcizumab in NSCLC

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OncoMed Pharmaceuticals, Inc. has entered into a clinical supply agreement with Eli Lilly and Co. to supply Alimta for OncoMed’s ongoing Phase II DENALI trial. The trial will evaluate Demcizumab, OncoMed’s anti-DLL4 antibody in combination with Lilly’s Alimta (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC).   Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or met...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters